Figure FS8 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer
Open Access
- 27 November 2025
- other
- Published by American Association for Cancer Research (AACR)